

Local Coverage Determination (LCD): MolDX: Chromosome 1p/19q Deletion Analysis (L36542)

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

Contractor Information

Contractor Name	Contract Type	Contract Number	Jurisdiction	State(s)
Noridian Healthcare Solutions, LLC	A and B MAC	02101 - MAC A	J - F	Alaska
Noridian Healthcare Solutions, LLC	A and B MAC	02102 - MAC B	J - F	Alaska
Noridian Healthcare Solutions, LLC	A and B MAC	02201 - MAC A	J - F	Idaho
Noridian Healthcare Solutions, LLC	A and B MAC	02202 - MAC B	J - F	Idaho
Noridian Healthcare Solutions, LLC	A and B MAC	02301 - MAC A	J - F	Oregon
Noridian Healthcare Solutions, LLC	A and B MAC	02302 - MAC B	J - F	Oregon
Noridian Healthcare Solutions, LLC	A and B MAC	02401 - MAC A	J - F	Washington
Noridian Healthcare Solutions, LLC	A and B MAC	02402 - MAC B	J - F	Washington
Noridian Healthcare Solutions, LLC	A and B MAC	03101 - MAC A	J - F	Arizona
Noridian Healthcare Solutions, LLC	A and B MAC	03102 - MAC B	J - F	Arizona
Noridian Healthcare Solutions, LLC	A and B MAC	03201 - MAC A	J - F	Montana
Noridian Healthcare Solutions, LLC	A and B MAC	03202 - MAC B	J - F	Montana
Noridian Healthcare Solutions, LLC	A and B MAC	03301 - MAC A	J - F	North Dakota
Noridian Healthcare Solutions, LLC	A and B MAC	03302 - MAC B	J - F	North Dakota
Noridian Healthcare Solutions, LLC	A and B MAC	03401 - MAC A	J - F	South Dakota
Noridian Healthcare Solutions, LLC	A and B MAC	03402 - MAC B	J - F	South Dakota
Noridian Healthcare Solutions, LLC	A and B MAC	03501 - MAC A	J - F	Utah
Noridian Healthcare Solutions, LLC	A and B MAC	03502 - MAC B	J - F	Utah
Noridian Healthcare Solutions, LLC	A and B MAC	03601 - MAC A	J - F	Wyoming
Noridian Healthcare Solutions, LLC	A and B MAC	03602 - MAC B	J - F	Wyoming

[Back to Top](#)

LCD Information

Document Information

LCD ID: L36542
Original Effective Date: For services performed on or after 08/01/2016

LCD Title: MolDX: Chromosome 1p/19q Deletion Analysis
Revision Effective Date: For services performed on or after 01/01/2017

AMA CPT / ADA CDT / AHA NUBC Copyright Statement
CPT only copyright 2002-2017 American Medical Association. All Rights Reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Revision Ending Date: N/A
Retirement Date: N/A
Notice Period Start Date: 06/15/2016
Notice Period End Date: 07/31/2016

The Code on Dental Procedures and Nomenclature (Code) is published in Current Dental Terminology (CDT). Copyright © American Dental Association. All rights reserved. CDT and CDT-2016 are trademarks of the American Dental Association.

UB-04 Manual. OFFICIAL UB-04 DATA SPECIFICATIONS MANUAL, 2014, is copyrighted by American Hospital Association ("AHA"), Chicago, Illinois. No portion of OFFICIAL UB-04 MANUAL may be reproduced, sorted in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior express, written consent of AHA." Health Forum reserves the right to change the copyright notice from time to time upon written notice to Company.

CMS National Coverage Policy CMS Internet Online Manual Pub. 100-02 (Medicare Benefit Policy Manual), Chapter 15, Section 80, "Requirements for Diagnostic X-Ray, Diagnostic Laboratory, and Other Diagnostic Tests"

CMS Internet-Only Manuals, Publication 100-04, Medicare Claims Processing Manual, Chapter 16, §50.5 Jurisdiction of Laboratory Claims, 60.12 Independent Laboratory Specimen Drawing, 60.2. Travel Allowance.

CMS Internet Online Manual Pub. 100-04 (Medicare Claims Processing Manual), Chapter 23 (Section 10) "Reporting ICD Diagnosis and Procedure Codes"

CMS Internet-Only Manual, Pub 100-04, Medicare Claims Processing Manual, Chapter 12, §30-Correct Coding Policy

Coverage Guidance

Coverage Indications, Limitations, and/or Medical Necessity

Indications for testing

Chromosome 1p-/19q- (e.g., glial tumors), deletion analysis is considered medically necessary for the management of following glial tumors:

- Astrocytoma
- Ependymoma
- Oligoastrocytoma (Mixed Glioma)
- Oligodendroglioma
- Optic Glioma
- Gliomatosis Cerebri

Chromosome 1p-/19q-deletion analysis may also be indicated in the diagnosis of neoplasms that exhibit small round cell features (e.g. small glioblastomas and neurocytic tumors)

Limitations of coverage

Chromosome 1p-/19q- deletion analysis may be accomplished by molecular sequencing (81402) or morphometric analysis (e.g. in situ hybridization (FISH) 88367 or 88368). Physicians with patients who meet the indications of chromosome 1p-/19q testing - may select from one of the following test services:

- 81402 Chromosome 1p-/19q- (e.g., glial tumors), deletion analysis
- 88367 Chromosome 1p-/19q- Morphometric analysis, in situ hybridization (quantitative or semi-quantitative), using computer-assisted technology, per specimen; initial single probe stain procedure
- 88373 Chromosome 1p-/19q- Morphometric analysis, in situ hybridization (quantitative or semi-quantitative), using computer-assisted technology, per specimen; each additional single probe stain procedure

- 88368 Chromosome 1p-/19q- Morphometric analysis, in situ hybridization (quantitative or semi-quantitative), manual, per specimen; initial single probe stain procedure
- 88369 Chromosome 1p-/19q-Morphometric analysis, in situ hybridization (quantitative or semi-quantitative), manual, per specimen; each additional single probe stain procedure

Note: Only **ONE** chromosome 1p-/19q analysis service per patient will be considered reasonable and necessary for tumor management.

Background

The presence of chromosome 1p/19q deletions in gliomas can assist in tumor differentiation, prognosis and treatment plan. Deletion studies specific to the 1p (short arm of chromosome #1) and 19q (long arm of chromosome #9) are performed on tumor tissue to determine if one or both 1p and 19q are deleted.

Over half of oligodendrogliomas have 1p/19q deletions that can help distinguish them from other types of gliomas.³ 1p/19q deletions can differentiate low-grade oligodendrogliomas from oligoastrocytomas.¹

The choice of adjuvant therapy depends on factors including tumor pathology and 1p/19q deletion status. Research observing improved survival has established combined procarbazine, lomustine, and vincristine (PCV) chemotherapy and radiation therapy as the new standard for treating anaplastic oligodendroglioma with the 1p/19q co-deletion.^{2,4,5,6}

[Back to Top](#)

Coding Information

Bill Type Codes:

Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the policy does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the policy should be assumed to apply equally to all claims.

0x TBD

Revenue Codes:

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the policy, services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the policy should be assumed to apply equally to all Revenue Codes.

N/A

N/A

CPT/HCPCS Codes

Group 1 Paragraph: N/A

Group 1 Codes:

- 81402 MOLECULAR PATHOLOGY PROCEDURE, LEVEL 3 (EG, >10 SNPS, 2-10 METHYLATED VARIANTS, OR 2-10 SOMATIC VARIANTS [TYPICALLY USING NON-SEQUENCING TARGET VARIANT ANALYSIS], IMMUNOGLOBULIN AND T-CELL RECEPTOR GENE REARRANGEMENTS, DUPLICATION/DELETION VARIANTS OF 1 EXON, LOSS OF HETEROZYGOSITY [LOH], UNIPARENTAL DISOMY [UPD])
- 88367 MORPHOMETRIC ANALYSIS, IN SITU HYBRIDIZATION (QUANTITATIVE OR SEMI-QUANTITATIVE), USING COMPUTER-ASSISTED TECHNOLOGY, PER SPECIMEN; INITIAL SINGLE PROBE STAIN PROCEDURE
- 88368 MORPHOMETRIC ANALYSIS, IN SITU HYBRIDIZATION (QUANTITATIVE OR SEMI-QUANTITATIVE), MANUAL, PER SPECIMEN; INITIAL SINGLE PROBE STAIN PROCEDURE
- 88369 MORPHOMETRIC ANALYSIS, IN SITU HYBRIDIZATION (QUANTITATIVE OR SEMI-QUANTITATIVE), MANUAL, PER SPECIMEN; EACH ADDITIONAL SINGLE PROBE STAIN PROCEDURE (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE)

88373 MORPHOMETRIC ANALYSIS, IN SITU HYBRIDIZATION (QUANTITATIVE OR SEMI-QUANTITATIVE), USING COMPUTER-ASSISTED TECHNOLOGY, PER SPECIMEN; EACH ADDITIONAL SINGLE PROBE STAIN PROCEDURE (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE)

ICD-10 Codes that Support Medical Necessity

Group 1 Paragraph: N/A

Group 1 Codes:

ICD-10 Codes	Description
C71.0	Malignant neoplasm of cerebrum, except lobes and ventricles
C71.1	Malignant neoplasm of frontal lobe
C71.2	Malignant neoplasm of temporal lobe
C71.3	Malignant neoplasm of parietal lobe
C71.4	Malignant neoplasm of occipital lobe
C71.5	Malignant neoplasm of cerebral ventricle
C71.6	Malignant neoplasm of cerebellum
C71.7	Malignant neoplasm of brain stem
C71.8	Malignant neoplasm of overlapping sites of brain
C71.9	Malignant neoplasm of brain, unspecified
C72.0	Malignant neoplasm of spinal cord

ICD-10 Codes that DO NOT Support Medical Necessity

Group 1 Paragraph: N/A

Group 1 Codes: N/A

ICD-10 Additional Information

[Back to Top](#)

[General Information](#)

Associated Information

CPT code 81402 descriptor was changed in Group 1, under CPT/HCPCS Codes. There may not be any change in how the code displays in the document.

Sources of Information and Basis for Decision

1. Buckner JC, et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. *J Clin Oncol.* 2003. 21(2):251-5.
2. Cairncross G, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. *J Clin Oncol.* 2013. 31(3):337-43. doi: 10.1200/JCO.2012.43.2674. Epub.
3. Cairncross JG, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. *J Natl Cancer Inst.* 1998. 90(19):1473-9.
4. Hoang-Xuan K, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. *J Clin Oncol.* 2004. 22(15):3133-8.

5. Ino Y, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res. 2001. 7(4):839-45.
6. Kaloshi G, et al. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology. 2007. 68(21):1831-6.

[Back to Top](#)

Revision History Information

Revision History Date	Revision History Number	Revision History Explanation	Reason(s) for Change
01/01/2017	R1	CPT code 81402 descriptor was changed in Group 1, under CPT/HCPCS Codes. There may not be any change in how the code displays in the document.	<ul style="list-style-type: none"> • Revisions Due To CPT/HCPCS Code Changes

[Back to Top](#)

Associated Documents

Attachments N/A

Related Local Coverage Documents Article(s) [A55081 - Response to Comments: MolDX: Chromosome 1p/19q Deletion Analysis](#) LCD(s) [DL36542](#) - (MCD Archive Site)

Related National Coverage Documents N/A

Public Version(s) Updated on 01/06/2017 with effective dates 01/01/2017 - N/A [Updated on 06/01/2016 with effective dates 08/01/2016 - N/A](#) [Back to Top](#)

Keywords

- 81402
- 88367
- 88368
- 88369
- 88373
- Chromosome Analysis
- Astrocytoma
- Ependymoma
- Oligoastrocytoma
- Mixed Glioma
- Oligodendroglioma
- Optic Glioma
- Gliomatosis Cerebri
-

Read the [LCD Disclaimer](#) [Back to Top](#)